WX

WebserviceX

Agentic AI Equity Research

Coverage blotter·Stock analysis hub·Note 2026-07-20·Latest →

Gilead Sciences (GILD) Stock Analysis

OW

GILD Equity Research — OVERWEIGHT — July 2026

← DHRISRG →

Rating date

Jul 20, 2026

21 days ago

Desk view

OW

5D move

—

Awaiting market data

Peer rank

72p

Research history

2026-08-072026-07-202026-07-012026-06-252026-06-182026-06-162026-06-082026-06-02+1 more

Investment card · GILD

Now I have comprehensive data. Let me compile the analysis.

Desk rating

OW

Tactical OW · 12M OW

Horizon

Short to medium term

Confidence

Medium

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Bias

OVERWEIGHT

Catalysts

  • GILD's long-term trend is intact — price is above both the 50- and 200-day SMAs, and the stock has gained ~27% over the trailing 12 months.
  • The medium-term trend is ambiguous. The declining 50-day SMA converging toward the rising 200-day SMA (near-death-cross territory) signals that intermediate momentum is waning.
  • Momentum is mixed but improving on balance. The MACD bullish crossover in early July is a constructive development, but the neutral RSI (~54.8) suggests the market has not yet committed to a new leg higher.

Risks

  • Event-driven repricing risk if expectations diverge from incoming evidence.

Market chart

Price context alongside the research narrative.

GILD Research Note

Full desk note for Jul 20, 2026. Use tabs for catalysts, valuation and risks, or open the full note.

30 min read

WebserviceX · Agentic Research Desk

GILD Equity Research Note

Published Jul 20, 2026 · Desk view OVERWEIGHT · Generated 2026-07-21T15:38:58Z · Maintained by Walter Vijayakumar · Methodology · Track record

GILD Stock Rating Summary

GILD bias

OVERWEIGHT

Horizon

Short to medium term

GILD key risk

Event-driven repricing risk if expectations diverge from incoming evidence.

GILD catalyst watch

GILD's long-term trend is intact — price is above both the 50- and 200-day SMAs, and the stock has gained ~27% over the trailing 12 months.

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Confidence

Medium

How the call aged · 5D

—Awaiting market dataPeer 72p
Expand

Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-07-21T15:52:24.190995+00:00.

5D move

—

2026-07-20 → awaiting

Outcome

Awaiting market data

5D trend

+1.38%

Vol (20D ann.)

+33.90%

vs SPY: +2.32%

Close 133.21 → — (USD, vendor closes)

Batch scorecard · 2026-07-20 · GILD

Publish QC

passed
Expand

Pipeline fingerprint 2f45a102687f75c0

Trace 14183834…

No QC issues recorded.